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Cambrosio et al. (2018. “Extending Experimentation: Oncology’s Fading
Boundary Between Research and Care.” New Genetics and Society 37 (3):
207–226) argue that “experimental care” in contemporary oncology involves
the rapid merging of patient research and care, and invite further study into
developments across other health conditions. We present a 2018–2019 study
of experimental breast cancer care in an urban clinical setting in the light of
two other studies in the same hospital group: in the same cancer service
(2013–14) and, prompted by these earlier findings, an interview study in
HIV services (2014–15). We found that patients and staff anticipated better
outcomes by treating sub-types of breast cancer but they also hoped for a
better one-size-fits-all approach, akin to the antiretroviral treatments
introduced for HIV and explored in our interview study. We conclude that
the promise of targeted treatment for sub-types of disease – variously
described as experimental care, personalised, precision, stratified and sub-
group medicine – is accompanied by hopes for a single, standard, effective
approach.
Keywords: Experimental; care; medicine; breast cancer; HIV
Introduction
Developments ranging from genomics to data analytics and the involvement of
patients and the public suggest a new dawn in biomedical research. Experimental
care, as we gloss these developments, is central to research that aims to improve
patient outcomes and it is known by a variety of other terms, including personal-
ised, precision, stratified and sub-group medicine. Rapidly evolving platforms
promise to deliver successful treatments based on a more precise classification of
disease types and perhaps novel aetiologies. Very often, this success is envisaged
through a contrast with a previous one-size-fits-all approach that delivered the
same treatment to everyone who had the same broad diagnosis. We argue,
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however, that today’s hopes ignore the diversity of previous and contemporary plat-
forms for research and care. These have led to exactly the broad standardised inter-
ventions – through vaccination or antiretroviral treatments for HIV for example –
that now seem outmoded as well as targeted interventions for subgroups. We hope
to show that research and care build on as they supplant previous platforms for
experimental care by looking at two different health conditions We ask in con-
clusion whether experimental care offers a better future of standardised as well
as subgroup treatments.
We adopt the term experimental care from Cambrosio, Keating and colleagues
(2018). They describe a merging of research and treatment which has involved
an unprecedented integration of biological and clinical research as well as data ana-
lytics since the 1990s. They suggest that these developments followed a period
after World War Two when the figure of the clinical researcher became somewhat
less central than previously. Incremental development of networked platforms has
since advanced to co-ordinate research practices with the management of data from
cancer research and cancer care (Keating and Cambrosio 2011, 2012). Cambrosio
et al. (2018) argue that “experimental care” in contemporary oncology is marked by
the routine use of trials and the rapid merging of patient treatment and research. It is
impossible, they argue, to differentiate research and treatment since patients are
invited to participate in research for which they are eligible and since research find-
ings are translated rapidly into new service protocols. Accordingly, they identify a
“fading boundary” or “vanishing distinction” between research and treatment
(2018, 208) because changes in the content, meaning, and boundaries of one
activity result in changes in the other.
In the UK, research and treatment have been variously demarcated and com-
bined. National Health Service (NHS) and private budgets were increasingly distin-
guished from the 1980s, and budgets for research were increasingly separated as
internal – and other – markets were introduced to the health system (Department
of Health 1989; Le Grand 1991; Mold 2010). Together with new public manage-
ment practices (Flynn 2012), marketisation also contributed indirectly to an
increasingly firm divide between clinical research, mostly in the form of drug
trials, and standard treatment. Currently, clinical staff and research governance in
services place boundaries around patients to protect them from formal research
(General Medical Council 2010). However, developments in -omics, in data collec-
tion and analysis, and policies encouraging collaboration between private and
public bodies have led to renewed emphasis on the interplay between research
and clinical practice. These developments inform the combination of research
and care in contemporary oncology and practices of classifying, identifying and
treating cancers. For example, multiple types of breast cancer were described in
2012 (Curtis et al. 2012), confirming a genetic heterogeneity that is associated
with increasingly precise therapeutic targeting. These new practices require the
wide participation of patients in both clinical trials and routine surveillance of out-
comes (NHS 2016; Davies 2017).
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Research in both social sciences and oncology agree that it is no longer possible
to readily distinguish research and standard treatment. Sacristán and Dilla, for
example, comment that “the classical separation between explanatory trials,
aimed at understanding, and pragmatic trials, aimed at decision, will become as
blurred as the frontier between research and care” (2018, 166). Moreover, the
classification of cancers has become uncertain and contested. Heterogeneous com-
binations of biomarkers, molecular pathways, treatment responses and the evol-
ution of cancers are difficult to align so as to distinguish clearly between
diseases that are defined in relation to previous categories such as anatomical
site and newer molecular features. This heterogeneity is addressed through
varied approaches: basket trials that assess an intervention across what were differ-
ent diseases; umbrella trials that test combination therapy in a single condition and
a variety of n of 1 studies, which include a single patient. Adaptive trial design is a
common way of addressing the heterogeneity that may only be defined post facto
(Mistry, Dunn, and Marshall 2017; Swallow et al. 2020).1 It remains an open ques-
tion how combination therapies can be trialed rationally, and which biomarkers
enable reasonable monitoring. Collaborations among scientists, regulatory organis-
ations, patient groups, and industry in the North American context where Cambro-
sio, Keating and colleagues have conducted much of their research, as well as
internationally, are critical to these developments. More generally, this team’s
work has contributed to social science and humanities research on experimental
practices as they are known in specific historical, organisational and epistemic situ-
ations (Hacking 1983; Galison 1987; Rheinberger 1997, 2010; Roepstorff and Frith
2012; Callard and Fitzgerald 2015).
We extend Cambrosio and colleagues’ concept of experimental care to clinical
interactions in a large, research-intensive NHS breast cancer service in London.
We reflect on our interview and observational data in the context of contributions
from the social sciences, humanities, and clinical medicine that have examined the
role that promise, expectation, and potential plays in this combination of research
and care (Hedgecoe 2004; Rajan 2017; Tutton 2012, 2014; Feiler et al. 2017;
Maughan 2017; Sturdy 2017). In the clinic, staff and patients attached a sense of
promise to experimental care, which might help identify types of breast cancer
and appropriate treatment. But their hopes were qualified by everyday uncertainties
about the evolution of a cancer, response to treatment, and eligibility for particular
treatments and inclusion in research studies. Possible therapeutic strategies were a
major focus of translational research, in which patients were invited to participate.
Although formal experimentation largely takes place in clinical trials, it is difficult
in clinical settings to draw firm lines between a platform for experimental care and
everyday clinical experimentation. Clinicians and patients routinely adjust and
adapt to the effects of therapy and the course of illness. Individuals may be pre-
scribed experimental or “off-label” treatment in the absence of clear evidence of
efficacy and safety, particularly when other treatments have failed and for patients
with a life-threatening or limiting condition (The Nuffield Council on Bioethics
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2018). Evidence-based medicine and treatment protocols are calibrated to particu-
lar situations through “tinkering” (Timmermans and Berg 1997; Bowker and Star
1999; Mol 2008). Uncertainties in everyday clinical interactions were expressed
in conversations. Could better outcomes be delivered for everyone through differ-
entiating types of breast cancer? Would the apparent antonym of “one-size-fits-all”
medicine, which has been realised historically for other health conditions, remain
relevant and, if so, how?
These questions led us to interview participants about experimental care in the
same hospital group’s HIV services in 2014–15 after conducting research from
2013–14 in breast cancer services. We then returned to the hospital group’s breast
cancer services to study developments from 2018–19. The relatively short history
of HIV care in the same setting allows us to ask questions of today’s experimental
cancer care. Our 2013–14 research in breast cancer services raised questions about
varied platforms for experimental care and we selected HIV medicine because of
our own backgrounds. Three of us worked in HIV and sexual health during the
early response in the 1980s and 1990s: an anthropologist in a sexual health clinic;
a clinician and public health researcher in sexual health and HIV; a senior nurse
specialist in HIV inpatient and outpatient care. Historically significant developments
preclude direct comparison between experimental care in breast cancer and HIV.
Changes in translational medicine, health policies and funding as well as the very
different aetiologies and populations constituted around these conditions and the
different contours of advocacy and collaboration all make direct comparison imposs-
ible. Our purpose is to suggest that hopes and uncertainties produced by experimental
breast cancer medicine and its markets (Dumit 2012; Gabe et al. 2012; Cohrs et al.
2014) are illuminated by reference to a history of HIV services. We focus on clinical
research priorities within paradigms of translational medicine – through which clin-
icians, researchers, patients, hospitals, bioinformatics and bioengineers, biotechnol-
ogy companies, and regulators cooperate and compete to shape the “normal” and
the “pathological” (Mittra and Milne 2013; Crabu 2018).
We first present research in breast cancer services during 12 months’ observation
and interviews, 2018–2019 and discuss developments. We then present results from
an interview study with patients and staff in HIV services (2014–15) from the same
hospital group, but across two different sites. In discussion, we highlight continu-
ities in biomedical approaches amidst otherwise incommensurable dimensions of
breast cancer and HIV services. We ask about the implications of exploring exper-
imental cancer care today through an earlier platform in another service area of this
hospital group. What questions and possibilities are raised by considering such past
futures?
Methods
Previously, we reported our findings from 2013–14 (Day et al. 2016;
Mc Grath-Lone et al. 2015; Mc Grath-Lone et al. 2015). Our fieldwork methods
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in 2018–2019 mirrored the combination of observation and interview in the earlier
study. We observed the main outpatient clinic and accompanied staff or patients to
other parts of the clinical pathway, such as chemotherapy services and multidisci-
plinary team meetings. In 2018–2020 we interviewed 54 staff and patients, includ-
ing 11 who had participated in the previous study. Three researchers (WV, SD, HW)
carried out observation and interviews, and kept field notes. Interviews were
recorded and transcribed verbatim, coded and analysed in NVivo12. Key themes
were identified and discussed in monthly team meetings before coding, enabling
a shared foundation for continuing fieldwork. The integration of these varied
data enabled fuller interpretation: interview material was extended by observations
across different settings, while fieldwork notes were elaborated in the light of indi-
vidual and collective views and explanations.
We selected a subset of interviews from a 2014–15 study to include those with
experience of HIV services in the later 1990s. We interviewed 11 people with HIV
who were diagnosed before effective antiretroviral therapy (ART) became widely
available in 1997 and 8 members of staff. These interviews were also recorded
and transcribed verbatim, coded and analysed in NVivo12. Key themes were devel-
oped through a systematic process of reading, rereading, coding and summarising
transcripts and subsequent in-depth analysis of the dataset. Final themes were dis-
cussed in the research group, focussing on experiences before and after the intro-
duction of effective ART (Bruton, Rai, Day, and Ward 2018; Rai et al. 2018).
Themes relating to combinations of research, care, and treatment outcomes were
compared iteratively across the three studies.
Breast cancer services
In our earlier work, staff and patients described problems in receiving and deliver-
ing services, which we considered in relation to both government measures and the
complexities of translating developments into existing services (Day et al. 2016).
We found on our return a continuing emphasis on biomedical research and the
promise of genomics, linked to widespread participation of patients in digital plat-
forms to manage both NHS and research data. However, patients and staff rarely
referred to “experimental care” or related terms such as “stratified”, “personalised”
or “precision” medicine.
Despite initiatives to better manage a complex pathway (Day et al. 2016), staff in
this London hospital group reported that pressures on the service had increased in
the face of growing workloads and more intensive treatments over the past five
years. Staff and patients alike credited some constraints, such as shortages of
space and staff, to UK government rationing. Other difficulties were attributed to
developments in biomedical research and their impact on clinical practice. An
oncologist noted, “twenty-five years ago, each type of cancer had two, two or
three, types of treatment but now each has got ten types.”2 In interviews, both
staff and patients described how treatment kept people with metastatic disease
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alive for longer. They also reported that treatment required more monitoring,
liaison and intricate adjustments. For example, a doctor explained problems of
resistance to a patient as he recommended a new regimen, “We find that adding
one [drug] onto another in a version of combination therapy works to turn breast
cancer into a chronic disease.” Some of the drugs were new; for example,
CDK4/6 inhibitors (in combination with aromatase inhibitors) have been intro-
duced since our previous study.3 They are taken orally, are far less toxic, and do
not cause hair loss. Initially available to patients with locally advanced or second-
ary cancer that is both hormone positive and HER2 (human epidermal growth
factor receptor 2) negative, the use of CDK4/6 inhibitors in combination with
other treatments and in other types of breast cancer continues to be trialed (e.g.
Sobhani et al. 2019). Patients on these treatments were scanned more frequently
but there were not enough radiologists to report the additional computerised tom-
ography (CT) scanning. An oncologist complained, “With some of the new drugs
like the CDK inhibitors, we used to scan them three monthly and now we see them
at least every month… in the past, they would have been on hormone therapy.… If
a scan isn’t reported and I’m not sure what the result is…we need to scan those
patients frequently to make sure they are responding. To make sure that it’s best
for the patient…” Such judgments also required close liaison among staff, often
across service areas. Patients were living longer, often with metastatic disease
and other conditions and, as a doctor explained, she now had to work with special-
ists across the hospital: in neurology, neurosurgery, gynaecology, hepatology, car-
diology and so on; “We have spread, we touch everything as patients have multiple
appointments with different specialists. They get problems in every system.”
The milieu remained challenging. “There are”, said an oncologist, “no more
averages. I can quote averages from clinical trials, but we don’t know.” She
found it especially difficult when patients asked for advice on tumor sequencing,
circulating tumor DNA tests, or the immunotherapy they could buy from
Germany for €60,000: “[A test] may come back with lots of mutations that
there’s no drug for, or there may be several mutations. Which mutation do we go
to first? If there’s a drug, it’s not available, or they may have already had some
of that treatment, and there may be heterogeneity within a tumour. If we biopsied
a different part of that tumor or a different metastasis, that might throw up different
results.”
Patients continued to experience significant uncertainties alongside the burden of
treatment. NHS-approved algorithms produced scores that were difficult to inter-
pret as well as intermediate groupings where there were no clear guidelines (see
Kerr et al. 2019). Moreover, the cancer with which patients were at least provision-
ally identified was re-evaluated constantly. Proliferating types were rated and
ranked and some people were pleased to find they had “HER2 positive breast
cancer” in both our earlier and more recent research because they could benefit
from targeted therapy. In the mid-1980s, it was found that the HER2 protein recep-
tor affected the growth of some cancer cells. A treatment was developed,
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trastuzumab, licensed in the US in 1998 and the EU in 2000 under the brand name
Herceptin. Routine screening looks for amplification of the HER2 protein, which is
associated with around 20–25% of breast cancers (Arteaga et al. 2012). During a
recent (2018) group discussion in a neighbouring non-governmental organisation,
a participant asked about her metastatic disease. She praised research developments
but remained concerned about her own poor prognosis: “it’s all good so long as it
doesn’t mean that I can’t have something like Herceptin [trastuzumab] in a year’s
time when everything else has run out – if that would give me another six months.”
Trastuzumab is not a drug used to target her own kind of cancer, which was not
HER2 positive in the past. A nurse asked if she would have a repeated biopsy
and we wondered whether this might pick up changes suggesting her new
tumors were now, perhaps, 20–30% HER2 positive. This woman, like others,
was aware of the dynamic heterogeneity and mutability of cancers and she navi-
gated multiple classification schemes according to anatomy, histology, genomics
and likely evolution.
By contrast, as we reported previously, triple negative breast cancer was con-
sidered a bad type. The term, Triple Negative Breast Cancer (TNBC), was first
used in 2005 (Brenton et al. 2005) to describe approximately 15–25% of breast
cancers in which chemotherapy was the only treatment available, since they
cannot be treated with hormonal therapy or anti-HER2 agents (Pareja et al.
2016). TNBC is an umbrella term for an otherwise heterogeneous group of
cancers. Discussing the research-intensive nature of the hospital as we were
waiting in the outpatients’ department in 2013, Tina4 had said, “the trouble with
the research, although it’s very good for care here, is I am triple negative and
there have been no findings. It’s possible there will be developments. Maybe if
they keep me alive for them, I will benefit. Who knows?” It was a challenge to
identify with a tumor defined in the negative, that is, lacking the three biomarkers
which can be targeted. Tina had been a nurse herself and was learning about the
new biological landscape, complaining that there was nothing for her cancer and
her prognosis was worse than for other types. She concluded that hers was an
orphan disease and she saw herself as an orphan in an orphan population that
had to wait for improvements in research and care for their kind of cancer (Day
et al. 2016). In 2018, we learned, new immunotherapies showed some promise
for this type of cancer (Marra, Viale, and Curigliano 2019; see also Schmid et al.
2018).
Surrogate or biomarkers had not changed in routine monitoring and results from
measuring CA15–3, a carcinoma antigen that increases in most metastatic cancers,
remained an unreliable guide. Meeting a patient we knew from an earlier study, we
were greeted with a smile as she said her “marker”was 32. Almost at once, she said
this measurement did not really tell you anything but, she emphasised, in the bad
old days when she first attended services, it was 200 and, more recently, it was
higher than 32. She was therefore encouraged by the trend. In contrast, a young
woman was disappointed when she came into the clinic with new liver metastases.
New Genetics and Society 7
At one point, she asked, “how come the numbers go down and everyone says it
looks good – the tumours are shrinking. And then this?” Her doctor responded,
“well, it’s because it is all good until it’s not. With developing resistance, cancer
comes back all at once. We can’t tell beforehand.…Also, the mechanism is differ-
ent in every single person so we can’t even predict which treatment or course of
action will work in which patient. So, we try therapy that might work, like this
triple therapy, but we don’t know.” Outside the clinic, this doctor explained the
complexity of dealing with a situation in which every patient could be deemed
to have a different cancer.
In sum, we found that the atmosphere in clinical services was more hopeful than
five years ago: there were more therapeutic options and many patients thought they
would live better for longer, as did their clinicians. Nevertheless, some types of
cancer had no new treatment options, and results for most remained provisional.
Test results amplified as well as reduced ambiguity; they often led to further
tests, further biopsies and further efforts to work out whether your own cancer
could (now) fit into a category suggesting a different approach. In this environment,
as we elaborate below, women with metastatic disease especially considered that
they were treated and studied simultaneously through close monitoring and contin-
ual adjustments of regimen. Many were also invited to participate in formal
research studies.
Women with breast cancer in this service were and are invited to participate in
research. Even with careful screening beforehand, some were found to be ineligible
for the available studies but the majority enrolled in formally defined research.
Many participants considered that they enjoyed good care as they contributed
(Mc Grath-Lone et al. 2015; Mc Grath-Lone et al. 2015). Although consent pro-
cesses typically limit the formal return of trial results and caution participants
against expecting personal benefit, we found that patients were drawn to research
for a variety of reasons. They typically anticipated an enhanced form of care, with
more frequent contact with clinical and non-clinical staff, appointments in post-
treatment follow-up, and the opportunity to contribute to the care of future patients.
A single example illustrates the different experiences of Tina and Fiona. As the
service protocols for Tina ran out (see above), she continued to hope that she
might benefit from experimental cancer care even though she was not eligible at
the time to join any of the available studies. We met her in the waiting room
when she had come to understand that there was still nothing to help with her con-
dition and she was at “the end of the road”. Fiona, in contrast, had been found eli-
gible and was invited to participate in a trial. Towards the end of the study, she
wondered if she were a “freak” because she stopped meeting her co-participants
on the day that they used to wait together to see the same doctor in the same
clinic. It was just her alone. There was no response to her query in an online
chat group. What was wrong with her? An oncologist, we learned, responded care-
fully to this situation and explained that there was nothing wrong. The doctor
emphasised to the contrary how special Fiona was. Her cancer was not the same
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as others on the trial and it seemed to respond well to the drug, “It works on your
individual cancer; theirs was different.” To Fiona, experimental care at this point
was highly responsive to both her personal well-being and the goal of improving
knowledge. Departing the trial, she wondered about the chance of recurrence.
Although she was pleased not to come to the hospital so often, she lost the
support she had enjoyed from a research technician, who made her visits to the
service run smoothly and who facilitated referrals for health issues that were prob-
ably unrelated to cancer. The frustrations of discovering where you needed to be
when, to do what with whom, returned.
Although Cambrosio and colleagues associate experimental cancer care with a
distributed platform for research participation, which rapidly translates research
findings into service protocols, we found that staff and patients recognised the
benefits of joining formal research studies to obtain “better” care directly. Patients
participated in research not only because of their commitment to improving treat-
ment, most likely for future generations, but because they found that they enjoyed
continuity, better information and more frequent check-ups. Most patients and staff
stressed the additional monitoring that might detect “incidental”, that is, unrelated
health problems, which could then be addressed. Most participants considered that
formal research participation delivered better overall health care (see also Hallowell
et al. 2010; Kost et al. 2011).
Amidst these uncertainties, clinical researchers seemed to aspire to therapeutic
approaches that worked in the past as well as those that hold promise for the
future. One clinician in cancer services drew on historical precursors to situate
the present complexity of cancer treatment:
It would be better if we had one curative treatment. It’s a bit like tuberculosis before
antibiotics… there were hundreds of different treatments for tuberculosis before anti-
biotics, very complex surgical and other treatments. But then the moment triple
therapy was brought in, there was only one treatment for tuberculosis. So in 20
years’ time - it could be that - we have now got an incredible number of treatments
for these [breast cancer] patients. But, at the end of the day, in 20 or 30 years’ time, we
could only have one.
In the absence of established knowledge, it is not clear how to categorise patients
with what appear to be common or distinct health conditions. Whether or not this
clinician paints a likely future, he hopes for a single effective approach to whatever
comes to be described as a single disease. Perhaps too, he is drawing on the prin-
ciples of equity and access associated with NHS principles of collective provision.
Experimental breast cancer care is a dynamic translational platform that affects
clinical, research, patient, and corporate partners in different ways. Our interviews
and observations suggested that a fading boundary between research and care gen-
erates both hopes and uncertainties. These are reflected in the burden of reporting
and decision-making associated with the novelty and number of treatments. A
mixture of promise and confusion is produced by proliferating categories of
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disease that are evaluated by staff and patients against emerging evidence and the
changing experiences and expectations of patients participating in research-inten-
sive regimens.
HIV services
Cambrosio et al. (2018) note that care has long been shaped by research but con-
sider contemporary oncology a “forerunner” (2018, 221) in developing a novel
integration of care and research practices. They want to historicise the emergence
and revival of experimental care, “its repeated re-emergence and re-definition, and
the shifting relations between these two components” and they ask, “how general-
izable are our findings?” (2018, 213, 221). They look to parallel contemporary
developments in cardiology for an answer but we ask about historic developments
in HIV services. Periods of experimental care in numerous health conditions have
involved scientific research alongside responses to very sick people. Previous col-
laborations in experimental care may provide insight into the promissory timbre of
breast cancer medicine today. HIV research and treatment were tailored to individ-
ual responses and preferences as well as formal experimentation in the early years.
Subsequently, a far more uniform approach to treatment was developed. Genomic
medicine was unknown in early HIV services, but experimental practices spanned
laboratories, clinics, government, industry, advocacy and activism in efforts to care
for and sort patients according to individual and group responses. More precise
measurements developed, populations were stratified and experimental care was
tailored along various parameters.
HIV is a retrovirus with a small genome by comparison with cancers, recognised
as the cause of AIDS in the 1980s amidst a major public health crisis, great fear and
segregation. Discrimination against groups that were already stigmatised com-
pounded the difficulties for those with HIV, most of whom died in the early
days. The first UK patient with AIDS was treated in the hospital Trust where we
conducted research in breast cancer services towards the end of 1982 and since
that time there have always been in-patients with HIV/AIDS in the two hospitals
in which we have worked. Between 1982 and 1985, the number of patients
increased dramatically and took a fifth of the acute medical beds at one of the
two hospitals (Weber 2018). It was inconceivable to treat people in this health
crisis without carrying out research. Likewise, it was impossible to carry out
research without providing support and care to those affected by HIV. In both hos-
pital sites, early responses were mixed but services attracted staff who wanted to
work in the area alongside patients and advocates.
We interviewed 11 people with HIV who were diagnosed before 1997 when
ARTs became widely available and 8 members of staff. Some of those living
with HIV were diagnosed through their participation in research. Jim had been
living with HIV for more than thirty years at the time of interview, and explained
how he saw a television show about “this new mysterious illness” whose
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mechanism of transmission was unknown. Because he felt that his sexual orien-
tation made him “a prime candidate” he joined a research study that recruited
gay men for regular blood tests. He gave samples for about eighteen months
without agreeing to receive results. He then asked about his HIV status and a clini-
cal researcher confirmed that he was positive. “There were lots of unknowns,” he
explained “but those unknowns were unknown to everybody… back in 1985, we
were on a learning curve that was changing all the time.” Jim found support in the
Terence Higgins Trust, Body Positive, and other local groups and charities that
developed around clinical services. These relationships were contested, and
patients and advocates disputed as they shaped priorities and interpretation (see
Shilts 1987; Berridge and Strong 1993; Berridge 2002; Colvin 2014; Padamsee
2020).
Prior to 1997, experimental care had little impact on outcomes; those with HIV
participated in research and advocacy and continued to die prematurely – at least
one death a day in the services we knew in the 1980s, almost all of them young,
gay men. Staff could at best make patients comfortable and experiment with pallia-
tive interventions since there was little else to offer. Hospice services expanded and,
in hospitals, acute and palliative care introduced more extensive teamwork. HIV
provided a unique opportunity to develop nursing roles that worked in practice
and not just in theory, as ward teams moved from a task-allocated approach to
one of responsibility for individual patients. Accordingly, concepts of “individua-
lised” care were applied from nursing research conducted in the 1970s and 1980s in
the USA (Fairbrother, Mary, and Jeffrey 2015). Although this approach reflects
longstanding clinical values, it was newly applied and developed in HIV wards
during the 1980s and introduced to other service areas subsequently (Jane
Bruton in Nicholls and Rosengarten 2019, 43–4). It transformed the environment
in which these men lived and died.
Extensive research into the biology of HIV and treatment developed alongside
efforts to prevent transmission. HIV trials had unusually high participation rates
since many people living with HIV insisted on participating; they were also
highly politicised (Elbaz 1995). In the 1980s, an HIV physician recalled, “if you
took bloods, you had to tick a box indicating whether it was on an NHS, private
or research budget.” That said, “everyone wanted to join research studies”
(Weber, pers. comms., April 2019). The well-known, largely US organisation,
AIDS Coalition to Unleash Power (ACT-UP), pressured for wider availability of
experimental treatments and direct action by patients included attempts to identify
the active ingredients and therefore detect the placebos. Participants would pool
their pills and share them out in “guerrilla clinics” (Institute of Medical Ethics
Working Party 1992). Some patients became experts in pharmacology and “evi-
dence-based activism” grew in significance (Epstein 1996). In consequence, treat-
ments were made available through “compassionate release” before they were
approved (Merigan 1990). The physician quoted above emphasised, however,
“you had to learn from every single patient, and you could not divide patients
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into two categories. While only a subset participated in research, data from every
patient were used to increase understanding.”
The first specific drug, Zidovudine (AZT), had been developed in a US cancer
program and was approved for HIV treatment in 1987. However, research
showed that it did not prevent progression to AIDS and it was reported that you
would likely die at the same time as you would without the drug (Concorde Coor-
dinating Committee 1994). From 1991–1994, two key studies trialed combinations
of the three available therapies, AZT and two nucleoside analogues. In Europe, the
UK Medical Research Council, with its background in tuberculosis trials, created
the infrastructure and protocols for multinational evaluation. By the end of 1994,
it was clear that patients survived when AZT and a nucleoside were used in com-
bination. This marks a key transformation in experimental HIV care because these
studies suggested that a single, uniform protocol might work for everyone.
The effect for patients was rapid. David, a man in his fifties at the time of inter-
view in 2014, recalled moving onto AZT, lamivudine (3TC) and ritonavir in 1996,
as soon as this combination therapy became available. He had followed the Con-
corde study closely and recalled differences in opinion about when to start treat-
ment. He felt that it was best to “start early” as soon as his CD4 count –
measurement of a glycoprotein that helps to track the relative function of a patient’s
autoimmune response – neared 500. He remembers how difficult the new drugs
were to get right – “high-dose ritonavir as an HIV treatment was pretty awful” –
and he switched to other combinations. Now, he explained, this is a treatment
reserved as a “booster” since it causes upset stomachs and nausea. David felt it
was worth it, and still felt after many years living with HIV that he might owe
his life to the chance he enjoyed.
As simple and widely tolerated regimens became available, clinical interactions
became more streamlined. They were guided by more uniform protocols with
minimal monitoring:
Before effective drugs came in, obviously there was a degree of certainty about how
patients would be managed in terms of that holistic approach to care, because it was
care and there wasn’t that sense of cure.… But when treatment came in all of that got
turned upside down (Jane Bruton quoted in Nicholls and Rosengarten 2019, 43).
Simultaneously, relationships between staff and between staff and patients became
more hierarchical. David (cited above) described how contemporary services were
“a bit more functional”; the doctors told him “‘we’ll check everything is okay”’
whereas “it used to be people would share [tests results] and talk you through
them.” As staff members corroborated, patients who once saw the same clinician
on a regular 2 or 3-monthly basis now had a blood test every six months and an
appointment with a clinician once a year.
Sandra remembered the rich network of organisations that supported people
affected by HIV in London after her diagnosis in the early 1990s. Her clinician
was always available but at the time of interview:
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I’m lucky if I get three or four minutes with him now. All they’re interested in is, are
you undetectable? That’s all they care about […] They just want to check my CD4
count and viral load. They don’t actually care for me. They provide me my treatment
and take my blood. That’s it. There’s not any care so to speak. Well they don’t.
There’s not time.
Sandra felt that monitoring had displaced the more expansive form of experimental
care she enjoyed in the past. A clinician we spoke to agreed: “We’re totally fixated
on these sodding [i.e. damn] numbers.”
General Practitioners (GPs) play a greater role than they did in the care of those
affected by HIV (Matthews et al. 2016; Baylis et al. 2017; Rai et al. 2019). Alan,
another man in his fifties who we met in 2015, explained his problems navigating
this new division of labor: “I know that, although my GP is very good, their time is
limited. They confess to not being terribly knowledgeable on HIV, which is fair
enough. They’ve got thousands of patients with thousands of other conditions to
be dealing with, so it’s understandable that the GP refers me to the clinic, which
is the centre of excellence.” The referrals were not a problem, he felt, until he
got to the hospital clinic where he might be told, “‘well, you need to speak to
your GP about that.’ I think, ‘Hello. I’ve been referred here, and now you’re
sending me back,’ so, sometimes, it feels that there is a bit of a ping pong, and
it’s a waste of everybody’s time if that happens.”
Specialist clinics no longer have the capacity and links to other services that they
once enjoyed. Effective antiretroviral therapy (ART) was one factor that promoted
the recalibration of tasks across varied health conditions, alongside the need to
budget for the cost of therapy for greater numbers within the NHS and wider pol-
itical priorities to reduce the cost of public services. “Once antiretrovirals came in,
then we needed to shrink” (Jane Bruton quoted in Nicholls and Rosengarten 2019,
20); wards shut, and staff lost their jobs. As a healthcare professional observed of
her patients, “now that we’ve got good antiretroviral drugs, we can treat them, but
there are a lot more problems with living arrangements, working arrangements, eli-
gibility to be in the country, psychiatric illness, co-infections like tuberculosis or
hepatitis.” A clinician contrasted the responsiveness of earlier services to a contem-
porary “medical sense of a cul-de-sac. It’s almost completely hopeless coming to
see me because whatever it is I diagnose as comorbidity, I am no longer in a pos-
ition to prescribe for and, hence, manage, which is bizarre and which makes my
clinics even more, if you like, from a strictly medical perspective, redundant”.
The professional quoted above said, “we’re having to actually push back patients
to their GPs.”
Initial HIV treatment today is adapted to individual and host genotyping but sub-
sequent regimens are highly standardised. With simpler regimens, patients are
increasingly encouraged to monitor their own health (see Beckmann 2013;
Hildebrandt, Bode, and Ng 2019).5 HIV has become a chronic condition for the
majority; services have been streamlined, and – in a UK climate of economic
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austerity – reduced. Interviews documented problems that arose as HIV services
were aligned with other services in the hospital group, which meant that outpatient
clinics needed to be reorganised. They also documented contingent developments.
But they did not provide much detail on the benefits of ART since these are now
almost taken for granted. For the majority, effective treatment has replaced exper-
imental care with a largely uniform approach that gives people with HIV in the UK
a normal life span. Experimental HIV care led to a virtually one-size-fits-all
approach, and this uniform approach is strikingly successful, at least as far as treat-
ment of uncomplicated cases is concerned. We therefore suggest avenues for under-
standing the current promise of translational research from an obvious perspective
that asks about the possible consequences of effective treatment.
Discussion
Platforms for experimental care have changed substantially in the space of twenty-
five years. Some tools are largely automated, such as digital imaging and risk
scoring through standard protocols and a variety of decision support tools. In
breast cancer services, gene sequencing is more common, not just for diagnostics
but also for tracking the evolution of cancer in individual patients (Coombes
et al. 2019). Analysis depends on the processing of large, digitised collections of
data (Bourret and Cambrosio 2019), managed through platforms that are increas-
ingly interoperable. Breast and other cancer aetiologies continue to change in
response to genomics research (e.g. Rueda et al. 2019), and monitoring of treatment
response remains critical to the continuing calibration of biological profiling and
treatment options within and across breast cancer types. In HIV services, by con-
trast, the only routine element of this kind adopted in protocols involved genotyp-
ing the virus to check for resistance and the host for a polymorphism that
gives adverse reactions to one of the alternative first line drugs, abacavir (Mallal
et al. 2008).
Many terms link these and other components of experimental care today. One
was coined by Leroy Hood and colleagues under the rubric of P4 cancer medicine
(Hood and Friend 2011). It involves widespread Participation in a more Personal-
ised cancer medicine, that is, an approach that tracks response to interventions
based on the cancer type that an individual shares with others. This form of strati-
fication is dynamic since individual monitoring and emerging data analytics lead to
continuing recalibration, making P4 medicine ideally Preventive and Predictive
(see Flores et al. 2013; Pokorska-Bocci et al. 2014; Academy of Medical Sciences
2015). National initiatives have opted for the terms Precision Medicine and Person-
alised Medicine (Schleidgen et al. 2013; Chadwick 2017; Erikainen and Chan
2019). NHS England, for example, adopted the term “personalised medicine” in
2016. Their webpages link to a National Genomic Medicine Service that was
launched in 2018 following Genomics England’s 100,000 Genomes Project (Geno-
mics England nd).6 In the future, NHS England aims to use “cutting edge genomic
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technologies to predict and diagnose inherited and acquired disease, and to person-
alise treatments and interventions” through this new service, particularly for those
with rare diseases and cancer, which will pave the way for advances in other
(common) conditions (NHS England 2018). NHS England acknowledges that
monitoring the course of an illness and applying evidence to different circum-
stances means that clinicians “have been working to personalise care, tailored to
people’s individual health needs, throughout the history of medicine” (NHS
England 2016; see also Tutton 2012, 2014). They also acknowledge associated
terms as with the USA’s Precision Medicine Initiative (2015) and, since 2018, its
national cohort, “All of Us”.
Staff and patients in the London breast cancer and HIV services where we con-
ducted research rarely used any of these terms unless prompted. Since we wanted to
explore the hope and promise associated with platforms for experimental care, we
did however elicit discussion of terms that could have specific associations, refer-
ents, strategic uses and serve as synonyms (see Erikainen and Chan 2019). Staff
referred readily to what they perceived as an older synonym, stratified medicine.
Some also explained that it was wise to frame bids for research funding in the
terms of precision or personalised medicine but showed little interest in their par-
ticular inflections. In contrast to academic commentaries and policy documents, it
is striking how far staff and patients avoided the contemporary vocabulary of
personalisation, precision and allied terms in this research-intensive London
hospital group.
Across these different but overlapping terms is a common thread. To take the
example of NHS England, their Personalised Medicine Strategy describes “a
move away from a ‘one-size-fits-all’ approach to the treatment and care of patients
with a particular condition…” (Keogh 2015; NHS England 2016). Contemporary
developments are conceived through a contrast with what is described as a pre-
vious, sometimes ineffectual and dangerous one-size-fits-all approach, which
failed to differentiate categories of disease in sufficient detail (see Connor 2003).7
We do not look to transitions from more experimental to more standardised
approaches in HIVas a way of imagining future breast cancer medicine; HIV medi-
cine continues to build on platforms for experimental care in translational studies,
basic science, epidemiology and public health, and other fields. To the contrary we
suggest that oncology’s present, constituted by a fading boundary between research
and care, is illuminated by an earlier phase of experimental care in another disease
condition. Sociologies of promise, expectation and potentiality have focussed on
the constitutive role of promise and expectation in forging biotechnological inno-
vation and the speculation necessary to craft collaborations, resources, and markets
that seek to bring futures into the present (Brown 2003; Brown and Michael 2003;
Rajan 2006; Martin, Brown, and Turner 2008; Fortun 2008; Adams, Murphy, and
Clarke 2009; Tutton 2012; Taussig, Hoeyer, and Helmreich 2013; Haase, Michie,
and Skinner 2015). Of special relevance to our research on contemporary oncology
is the shift in perspective afforded by looking at the short history of HIV research
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and care. As Brown suggests (2003, 10), “expectations of the future change over
time. That is, our presents are situated in relation to memories of past futures
and future presents.” Commentators have identified unrealistic and harmful expec-
tations attached to precision or personalised medicines (see Feiler et al. 2017; Eri-
kainen and Chan 2019). Some note the shortfall between promise and reality, and
describe the failure of personalised medicine to achieve personal or public benefits
(Prasad 2016; Dickenson 2011; Rushforth and Greenhalgh 2020); others consider
that distortions are introduced to clinical consultations, resource and research
funding priorities (e.g. Maughan 2017). The deep links between financial econom-
ies of promise and pharmacogenomic development are well documented (Hedge-
coe and Martin 2003; Tutton 2014; Sturdy 2017), and track the close
relationships between corporate lobbying and patient advocacy (Brown 2003;
Panofsky 2010). Concerns have been expressed about how these trends may
erode solidaristic approaches to healthcare, commodifying “participant-patients”
(Prainsack 2017). These contributions have been associated with a range of
terms and practices, which we have gathered under the rubric of experimental care.
We have shown that hopes pinned to experimental breast cancer care today are
accompanied by doubts and uncertainties: a patient may dispute the apparent stab-
ility of her cancer type since it precludes alternative treatment; a clinician may
despair of predicting resistance in patients; a clinical researcher may hope for a
uniform and effective approach on the model of past advances in tuberculosis
care. Initial breast cancer treatment for many people is less enmeshed in experimen-
tal practices, like uncomplicated HIV treatment, but overall breast cancer care con-
stitutes an expansive field that includes what are now considered to be many
distinct health conditions. Both staff and patients hoped that developments in trans-
lational medicine would fulfill their promise (Vecchio et al. 1990) but new bio-
technologies, pharmacogenomics or policy had no more purchase than
considerations of clinical effectiveness.
We have also shown that interview participants attributed contemporary stan-
dards for the management of HIV to a previous epoch of experimentation.
Developments in experimental HIV care lasted little more than a decade, from
the early-1980s to the mid-1990s when dated to the first effective treatment. It
took another decade to resolve difficulties with dosage, toxicity and side effects
(WHO 2006), and to register the effects of the 2008 financial crisis on public
services, including the UK health system. HIV patients had participated widely
in research and advocated for the rapid translation of research findings into treat-
ment protocols. Although most did not benefit from treatment directly in the
early days, their participation was critical to clinical and laboratory research and
to the eventual effective “universal test and treat” approach taken in the 2010s
(Lancet 2015; Hayes et al. 2019). Experimental care led to standard protocols for
uncomplicated HIV treatment. In retrospect, some patients and staff regretted the
loss of close partnerships that enabled navigation from one appointment to
another and between different service areas. But their hopes for better clinical
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outcomes were fulfilled. Our interview study confirmed retrospective benefits from
experimental care that led, not to the proliferation of ever-smaller disease groupings
through targeted treatments, but to a more standardised approach that gave patients
a normal life span. Historically, effective biomedical treatments have led to
renewed calibration between individual and group – virtually a return to the one-
size-fits-all approach for uncomplicated HIV care.
Conclusion
Since care is only king in the absence of cure or prevention – for example, through
vaccination – our conclusion is so obvious that the only puzzle is its absence, to our
knowledge, from discussions of contemporary experimental care. Proponents of P4
medicine imagine a virtuous circle in which success is forever deferred: more
precise and effective treatment will continue to require more knowledge, which
will continue to require the participation – and reciprocal care – of those affected
and, indirectly, whole populations to which these individuals belong. This
variety of future suggests that disease types and biotechnology markets will con-
tinue to proliferate. Biomedical idioms of success and failure may indeed change
along with concepts of person and population, new molecular and genetic aetiolo-
gies, and the increasingly blurred boundaries between health, disease risk and
disease. But experiences in HIV and, indeed, TB translational research platforms
also suggest important continuities in efforts to improve outcomes. In this
context, success and failure may differentiate standard as opposed to experimental
care.
Our analysis foregrounds a countervailing hope for a more standardised treat-
ment that can be given to almost everyone, and earlier experiences in HIV continue
to provide models for other experimental care platforms, not least SARS-CoV-2.
None of the health conditions in this hospital group are directly comparable but
research and care build on as they supplant previous platforms for experimental
care.
Earlier combinations of treatment and care indicates the appeal that continues
to be invested in the apparent antonym of personalised medicine, that is, one-
size-fits-all. Examining biomedical criteria for success and failure as they apply
to the bundling of research knowledge, treatment outcomes and patient care
across diverse services, we ask whether it is plausible to imagine effective and
more stable combination therapies for breast cancers?
Even though the hoped-for success of the new is widely constructed through a
contrast with a previous one-size-fits-all medicine that has failed, we suggest that
this latter paradigm still attracts support in translational research. It is not just an
inadequate, harmful and outmoded approach. It remains both a goal and a
witness to past futures associated with NHS principles of equal access to appropri-
ate and effective care for all-comers. It is, in short, both companion and limit to the
ever-more precise differentiation of people and their health conditions.
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Notes
1. Adaptive trial design has been defined as “a clinical trial design that allows for prospectively
planned modifications to one or more aspects of the design based on accumulating data from
subjects in the trial” (FDA 2018, 2).
2. While quotations from transcripts are verbatim, signaled in the text using double quotation
marks, field note records from informal or group discussions are marked with single quotations.
3. Initially rejected in early 2017 by the National Institute for Health and Care Excellence (NICE)
for their high cost in relation to their prospective benefit, the CDK4/6 inhibitors, palbociclib
(Ibrance) and ribociclib (Kisqali), were licensed for use in the NHS in November 2017.
4. We use pseudonyms here and throughout this article.
5. We should acknowledge that NHS England have introduced a long-term strategy of Personalised
Care (2019) that aims to involve patients in their care. As commentators have noted, this process
can involve delegating responsibilities and work to “self-managing” patients.
6. See NHS England, “NHS Genomic Medicine Service”, https://www.england.nhs.uk/genomics/
nhs-genomic-med-service/ accessed 11th November 2019.
7. Connor notes that Allan Roses, a senior executive at GlaxoSmithKline, suggested that most drugs
currently on the market only worked in 30-50% of the population.
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